3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
6
Isotretinoin
5
thymoglobulin
4
fludarabine phosphate
4
fludarabine
4
aldesleukin
4
Topotecan
4
Temozolomide
4
Melphalan
4
Irinotecan
4
Etoposide
4
ribociclib
3
Thiotepa
3
Interleukin-2
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
temsirolimus
2
omburtamab I-131
2
dinutuximab
2
Vincristine
2
Tretinoin
2
TPI-287
2
Stem Cell Transplantation
2
Rituximab
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neuroblastoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts